In short
Clinical trials are investigating AZD0120 in people with relapsed or refractory multiple myeloma, a cancer that has returned or no longer responds to treatment. These studies aim to compare AZD0120 with standard therapy and measure how well it works and how safe it is. The main focus is on adults with this blood cancer in a Phase 3 trial.
Key points
- AZD0120 is being studied in a Phase 3 clinical trial for people with relapsed or refractory multiple myeloma. The trial compares AZD0120 with standard therapy options such as DKd, DPd, PVd, or Kd. Researchers want to see whether AZD0120 improves progression-free survival and the rate of MRD negative complete response at 9 months. The study is interventional and has an enrollment of 508 people. The trial is currently authorised.
Trial overview
This clinical trial is studying AZD0120 in people with relapsed or refractory multiple myeloma. The trial is designed to see how well AZD0120 works and how safe it is compared with standard therapy.
Who the trial is for
The trial is for people with relapsed or refractory multiple myeloma. Relapsed means the cancer came back after treatment, and refractory means the cancer did not respond well to treatment.
What the study measures
The main outcome is progression-free survival (PFS), which is the time from randomisation until the cancer gets worse or the person dies from any cause, whichever happens first. The trial also measures the MRD negative complete response rate at 9 months, which means the share of people who have no measurable residual disease and a complete or stringent complete response at that time point.
Treatments being compared
The study compares AZD0120 with standard therapy options listed as DKd, DPd, PVd, or Kd. These are treatment combinations used as the control group, so the researchers can see whether AZD0120 gives better results.
- DKd is one of the standard therapy options named in the trial.
- DPd is one of the standard therapy options named in the trial.
- PVd is one of the standard therapy options named in the trial.
- Kd is one of the standard therapy options named in the trial.
Study design and phase
This is an interventional study, which means the researchers give treatment and then measure the results. It is a Phase 3 trial, which is a later-stage study that compares a new treatment with standard care in a larger group of people. The trial has an enrollment of 508 people and is currently authorised.
What the results mean for patients
The study is focused on whether AZD0120 can help people stay free from disease worsening for longer than standard treatment. It also looks for deep responses, meaning the cancer is harder to detect with sensitive tests. These results help show whether AZD0120 may be a better option for people whose myeloma has returned or is not responding well.